Miniatura

Fitxers

1-s2.0-S1684118225000441-main.pdf (757.25 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2025-03-17

Llicència de publicació

cc-by-nc-nd (c) Hidalgo Tenorio, Carmen et al., 2025
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/222287

Real-world evidence of dalbavancin effectiveness as consolidation therapy in infective endocarditis due to Enterococcus spp

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.jmii.2025.03.001

Resum

Enterococcal endocarditis (EIE) affects elderly patients, with high rates of complications and mortality, and dalbavancin (DBV) exhibits significant antimicrobial activity against most enterococci. However, data are lacking on the use of DBV in EIE. The main objective was to evaluate the outcomes of treatment with DBV in the consolidation therapy of IE by Enterococcus spp. Methods: Spanish-French retrospective observational study of patients with EIE enrolled between November 2016 and June 30, 2022 receiving DBV in consolidation phase and followed for >= 12 months. Results: Ninety-eight patients were enrolled, 69.4 % male, with mean age of 71.2 (+/- 12.51) years and median Charlson index of 5 (IQR 3-7). Criteria for definite IE were met by 84.7%; 60.2 % had IE on native valve, 26.5 % late prosthetic IE, 8.2 % early prosthetic IE, 2 % cardiovascular implantable electronic-IE (CIE-IE), and 3.1 % CIE-IE and valve. Aortic valve involvement was observed in 66.3 %. E. faecalis was isolated in 86.7 %, E. faecium in 11.2%; 32.6% underwent surgery, and these had a higher cure rate (100% vs 75.8 %; p = 0.005) and lower mortality (0 vs 13.6 %; p = 0.029). DBV was administered to facilitate discharge in 88.8 %. Total dose was 2500 mg (1500-3000) over 3.5 weeks (2-4). Loss to follow-up was 0%, relapse rate 8.2 %, 1-year IE-related mortality 3.1 %, and clinical cure rate 81.2 %. Severe adverse events affected 1 % (acute tubular necrosis). Hospital stay was reduced by 21 days (14-28). Conclusions: DBV appears to be highly effective, safe, and cost-effective as consolidation therapy in patients with IE caused by Enterococcus spp., with minimal adverse events.

Matèries

Endocarditis, Antibiòtics, Terapèutica

Matèries (anglès)

Endocarditis, Antibiotics, Therapeutics

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

HIDALGO TENORIO, Carmen, SADYRBAEVA DOLGOVA, Svetlana, APARICIO MINGUIJÓN, Eduardo, ALARCÓN, Arístides de, PLATA, Antonio, MARTÍNEZ MARCOS, Francisco javier, ÁLVAREZ ÁLVAREZ, Beatriz, LOECHES, Belén, VARISCO, Benedetta, ESTÉVEZ, Agustín, HERRERO, Carmen, ESCRIHUELA VIDAL, Francesc, BOIX PALOP, Lucia, RUCH, Yvon, VALOUR, Florent, ISSA, Nahéma, THILL, Pauline, NGUYEN, Sophie, POLONI, Samantha, MILLOT, Romain, PEIFFER SMADJA, Nathan, BOYER CHAMMARD, Timothée, DIALLO, Kevin, LARCHER, Romaric, MIRÓ MEDA, José m. (josé maría), LUQUE PAZ, David. Real-world evidence of dalbavancin effectiveness as consolidation therapy in infective endocarditis due to Enterococcus spp. _Journal of Microbiology Immunology and Infection_. 2025. Vol. 58, núm. 4, pàgs. 429-436. [consulta: 24 de gener de 2026]. ISSN: 1995-9133. [Disponible a: https://hdl.handle.net/2445/222287]

Exportar metadades

JSON - METS

Compartir registre